nodes	percent_of_prediction	percent_of_DWPC	metapath
Everolimus—CYP3A4—Rifampicin—leprosy	0.0703	0.548	CbGbCtD
Everolimus—CYP3A4—Dapsone—leprosy	0.058	0.452	CbGbCtD
Everolimus—Infertility male—Dapsone—leprosy	0.0539	0.0863	CcSEcCtD
Everolimus—Complex regional pain syndrome—Thalidomide—leprosy	0.0528	0.0845	CcSEcCtD
Everolimus—MTOR—hindlimb—leprosy	0.0459	0.243	CbGeAlD
Everolimus—MTOR—appendage—leprosy	0.0394	0.208	CbGeAlD
Everolimus—Blood phosphorus decreased—Thalidomide—leprosy	0.0219	0.0351	CcSEcCtD
Everolimus—MTOR—blood vessel—leprosy	0.0219	0.116	CbGeAlD
Everolimus—Disease progression—Thalidomide—leprosy	0.0146	0.0233	CcSEcCtD
Everolimus—Peritonitis—Thalidomide—leprosy	0.0126	0.0201	CcSEcCtD
Everolimus—Thromboembolic event—Thalidomide—leprosy	0.0118	0.0189	CcSEcCtD
Everolimus—MTOR—eye—leprosy	0.0117	0.0616	CbGeAlD
Everolimus—FKBP1A—eye—leprosy	0.0105	0.0554	CbGeAlD
Everolimus—MTOR—skin of body—leprosy	0.0101	0.0536	CbGeAlD
Everolimus—FKBP1A—skin of body—leprosy	0.00913	0.0482	CbGeAlD
Everolimus—Pyuria—Thalidomide—leprosy	0.00911	0.0146	CcSEcCtD
Everolimus—FKBP1A—Alpha-synuclein signaling—PARK2—leprosy	0.00779	0.136	CbGpPWpGaD
Everolimus—MTOR—tendon—leprosy	0.00773	0.0408	CbGeAlD
Everolimus—Proteinuria—Dapsone—leprosy	0.00707	0.0113	CcSEcCtD
Everolimus—Ascites—Thalidomide—leprosy	0.007	0.0112	CcSEcCtD
Everolimus—Protein urine present—Dapsone—leprosy	0.00698	0.0112	CcSEcCtD
Everolimus—FKBP1A—tendon—leprosy	0.00695	0.0367	CbGeAlD
Everolimus—Aphthous stomatitis—Thalidomide—leprosy	0.00678	0.0109	CcSEcCtD
Everolimus—MTOR—testis—leprosy	0.0064	0.0338	CbGeAlD
Everolimus—White blood cell count decreased—Thalidomide—leprosy	0.00639	0.0102	CcSEcCtD
Everolimus—Embolism venous—Thalidomide—leprosy	0.0063	0.0101	CcSEcCtD
Everolimus—MTOR—nervous system—leprosy	0.00628	0.0332	CbGeAlD
Everolimus—Lymphopenia—Thalidomide—leprosy	0.00622	0.00995	CcSEcCtD
Everolimus—Skin exfoliation—Dapsone—leprosy	0.00593	0.00949	CcSEcCtD
Everolimus—FKBP1A—testis—leprosy	0.00575	0.0304	CbGeAlD
Everolimus—FKBP1A—nervous system—leprosy	0.00565	0.0298	CbGeAlD
Everolimus—Foetor hepaticus—Thalidomide—leprosy	0.00561	0.00897	CcSEcCtD
Everolimus—Blood lactate dehydrogenase increased—Thalidomide—leprosy	0.00547	0.00876	CcSEcCtD
Everolimus—Platelet count decreased—Thalidomide—leprosy	0.00535	0.00856	CcSEcCtD
Everolimus—Deep vein thrombosis—Thalidomide—leprosy	0.00523	0.00837	CcSEcCtD
Everolimus—Serum creatinine increased—Thalidomide—leprosy	0.00517	0.00827	CcSEcCtD
Everolimus—Hypomagnesaemia—Thalidomide—leprosy	0.00501	0.00801	CcSEcCtD
Everolimus—Oral candidiasis—Thalidomide—leprosy	0.00501	0.00801	CcSEcCtD
Everolimus—Embolism—Thalidomide—leprosy	0.00496	0.00793	CcSEcCtD
Everolimus—Nail disorder—Thalidomide—leprosy	0.00491	0.00785	CcSEcCtD
Everolimus—Liver disorder—Thalidomide—leprosy	0.00467	0.00747	CcSEcCtD
Everolimus—FKBP1A—Calcium signaling in the CD4+ TCR pathway—CD40LG—leprosy	0.00459	0.0801	CbGpPWpGaD
Everolimus—Neuralgia—Thalidomide—leprosy	0.00458	0.00733	CcSEcCtD
Everolimus—Hypercalcaemia—Thalidomide—leprosy	0.00458	0.00733	CcSEcCtD
Everolimus—MTOR—Senescence and Autophagy in Cancer—TNFSF15—leprosy	0.0045	0.0785	CbGpPWpGaD
Everolimus—Interstitial lung disease—Thalidomide—leprosy	0.00449	0.00719	CcSEcCtD
Everolimus—Thrombosis—Thalidomide—leprosy	0.00449	0.00719	CcSEcCtD
Everolimus—Metrorrhagia—Thalidomide—leprosy	0.00445	0.00713	CcSEcCtD
Everolimus—Hyperlipidaemia—Thalidomide—leprosy	0.00441	0.00706	CcSEcCtD
Everolimus—Pleural effusion—Thalidomide—leprosy	0.00415	0.00665	CcSEcCtD
Everolimus—MTOR—IL4-mediated signaling events—LTA—leprosy	0.00404	0.0705	CbGpPWpGaD
Everolimus—Nasopharyngitis—Dapsone—leprosy	0.00403	0.00645	CcSEcCtD
Everolimus—Muscular weakness—Dapsone—leprosy	0.00398	0.00637	CcSEcCtD
Everolimus—Influenza—Dapsone—leprosy	0.0039	0.00624	CcSEcCtD
Everolimus—Endocrine disorder—Thalidomide—leprosy	0.00384	0.00614	CcSEcCtD
Everolimus—Pancreatitis—Dapsone—leprosy	0.00382	0.00612	CcSEcCtD
Everolimus—Blood disorder—Thalidomide—leprosy	0.00381	0.00609	CcSEcCtD
Everolimus—Acne—Thalidomide—leprosy	0.00378	0.00605	CcSEcCtD
Everolimus—Amenorrhoea—Thalidomide—leprosy	0.00362	0.00579	CcSEcCtD
Everolimus—Proteinuria—Thalidomide—leprosy	0.00362	0.00579	CcSEcCtD
Everolimus—Protein urine present—Thalidomide—leprosy	0.00357	0.00571	CcSEcCtD
Everolimus—Viral infection—Thalidomide—leprosy	0.00352	0.00564	CcSEcCtD
Everolimus—Cellulitis—Thalidomide—leprosy	0.0035	0.0056	CcSEcCtD
Everolimus—Hypocalcaemia—Thalidomide—leprosy	0.00348	0.00556	CcSEcCtD
Everolimus—Hyperuricaemia—Thalidomide—leprosy	0.00343	0.00549	CcSEcCtD
Everolimus—Leukocytosis—Thalidomide—leprosy	0.00339	0.00542	CcSEcCtD
Everolimus—Hypercholesterolaemia—Thalidomide—leprosy	0.00336	0.00538	CcSEcCtD
Everolimus—Creatinine increased—Thalidomide—leprosy	0.00334	0.00535	CcSEcCtD
Everolimus—Sinusitis—Dapsone—leprosy	0.00326	0.00522	CcSEcCtD
Everolimus—Blood uric acid increased—Thalidomide—leprosy	0.00324	0.00518	CcSEcCtD
Everolimus—Pulmonary embolism—Thalidomide—leprosy	0.00318	0.00509	CcSEcCtD
Everolimus—Phosphatase alkaline increased—Thalidomide—leprosy	0.00318	0.00509	CcSEcCtD
Everolimus—Hepatocellular injury—Thalidomide—leprosy	0.00318	0.00509	CcSEcCtD
Everolimus—Hyperkalaemia—Thalidomide—leprosy	0.00313	0.005	CcSEcCtD
Everolimus—Pharyngitis—Dapsone—leprosy	0.0031	0.00496	CcSEcCtD
Everolimus—Candida infection—Thalidomide—leprosy	0.00304	0.00486	CcSEcCtD
Everolimus—Skin exfoliation—Thalidomide—leprosy	0.00304	0.00486	CcSEcCtD
Everolimus—Blood urea increased—Thalidomide—leprosy	0.003	0.00481	CcSEcCtD
Everolimus—Rash maculo-papular—Thalidomide—leprosy	0.00289	0.00463	CcSEcCtD
Everolimus—Pulmonary oedema—Thalidomide—leprosy	0.00283	0.00453	CcSEcCtD
Everolimus—Sepsis—Thalidomide—leprosy	0.00276	0.00442	CcSEcCtD
Everolimus—Erythema—Dapsone—leprosy	0.00272	0.00435	CcSEcCtD
Everolimus—Lymphadenopathy—Thalidomide—leprosy	0.00271	0.00433	CcSEcCtD
Everolimus—FKBP1A—Calcium signaling in the CD4+ TCR pathway—IFNG—leprosy	0.0027	0.0471	CbGpPWpGaD
Everolimus—Blood alkaline phosphatase increased—Thalidomide—leprosy	0.00266	0.00425	CcSEcCtD
Everolimus—Diabetes mellitus—Thalidomide—leprosy	0.00266	0.00425	CcSEcCtD
Everolimus—Gastroenteritis—Thalidomide—leprosy	0.00261	0.00417	CcSEcCtD
Everolimus—Vision blurred—Dapsone—leprosy	0.00256	0.0041	CcSEcCtD
Everolimus—Cardiac failure congestive—Thalidomide—leprosy	0.00255	0.00407	CcSEcCtD
Everolimus—Renal failure acute—Thalidomide—leprosy	0.0025	0.004	CcSEcCtD
Everolimus—Dermatitis exfoliative—Thalidomide—leprosy	0.00245	0.00392	CcSEcCtD
Everolimus—Atrial fibrillation—Thalidomide—leprosy	0.00244	0.0039	CcSEcCtD
Everolimus—FKBP1A—Calcium signaling in the CD4+ TCR pathway—IL2—leprosy	0.0024	0.0418	CbGpPWpGaD
Everolimus—Cough—Dapsone—leprosy	0.00237	0.00379	CcSEcCtD
Everolimus—Cardiac failure—Thalidomide—leprosy	0.00237	0.00379	CcSEcCtD
Everolimus—Hypoglycaemia—Thalidomide—leprosy	0.00237	0.00379	CcSEcCtD
Everolimus—Lethargy—Thalidomide—leprosy	0.00236	0.00377	CcSEcCtD
Everolimus—Hyponatraemia—Thalidomide—leprosy	0.00232	0.00371	CcSEcCtD
Everolimus—Pain in extremity—Thalidomide—leprosy	0.00231	0.00369	CcSEcCtD
Everolimus—Migraine—Thalidomide—leprosy	0.00227	0.00364	CcSEcCtD
Everolimus—Cardiac arrest—Thalidomide—leprosy	0.0022	0.00351	CcSEcCtD
Everolimus—Tachycardia—Dapsone—leprosy	0.00216	0.00346	CcSEcCtD
Everolimus—Blood creatinine increased—Thalidomide—leprosy	0.00216	0.00346	CcSEcCtD
Everolimus—Dehydration—Thalidomide—leprosy	0.00215	0.00344	CcSEcCtD
Everolimus—Liver function test abnormal—Thalidomide—leprosy	0.00213	0.00341	CcSEcCtD
Everolimus—Dry skin—Thalidomide—leprosy	0.00212	0.00339	CcSEcCtD
Everolimus—Hypokalaemia—Thalidomide—leprosy	0.0021	0.00336	CcSEcCtD
Everolimus—Breast disorder—Thalidomide—leprosy	0.00209	0.00334	CcSEcCtD
Everolimus—Aspartate aminotransferase increased—Thalidomide—leprosy	0.00208	0.00333	CcSEcCtD
Everolimus—Alanine aminotransferase increased—Thalidomide—leprosy	0.00204	0.00326	CcSEcCtD
Everolimus—Muscular weakness—Thalidomide—leprosy	0.00204	0.00326	CcSEcCtD
Everolimus—Abdominal distension—Thalidomide—leprosy	0.00201	0.00321	CcSEcCtD
Everolimus—Insomnia—Dapsone—leprosy	0.00201	0.00321	CcSEcCtD
Everolimus—Influenza—Thalidomide—leprosy	0.002	0.00319	CcSEcCtD
Everolimus—Dysphagia—Thalidomide—leprosy	0.002	0.00319	CcSEcCtD
Everolimus—Bronchospasm—Thalidomide—leprosy	0.00196	0.00314	CcSEcCtD
Everolimus—Pancreatitis—Thalidomide—leprosy	0.00196	0.00313	CcSEcCtD
Everolimus—Angina pectoris—Thalidomide—leprosy	0.00194	0.00311	CcSEcCtD
Everolimus—Bronchitis—Thalidomide—leprosy	0.00192	0.00307	CcSEcCtD
Everolimus—Pancytopenia—Thalidomide—leprosy	0.0019	0.00303	CcSEcCtD
Everolimus—MTOR—IL12-mediated signaling events—RIPK2—leprosy	0.00188	0.0329	CbGpPWpGaD
Everolimus—Neutropenia—Thalidomide—leprosy	0.00187	0.00299	CcSEcCtD
Everolimus—Upper respiratory tract infection—Thalidomide—leprosy	0.00186	0.00297	CcSEcCtD
Everolimus—CYP3A4—nervous system—leprosy	0.00185	0.00975	CbGeAlD
Everolimus—Pollakiuria—Thalidomide—leprosy	0.00184	0.00295	CcSEcCtD
Everolimus—Erectile dysfunction—Thalidomide—leprosy	0.00184	0.00294	CcSEcCtD
Everolimus—Gastrointestinal pain—Dapsone—leprosy	0.00181	0.0029	CcSEcCtD
Everolimus—Weight decreased—Thalidomide—leprosy	0.00181	0.00289	CcSEcCtD
Everolimus—Hyperglycaemia—Thalidomide—leprosy	0.0018	0.00288	CcSEcCtD
Everolimus—Pneumonia—Thalidomide—leprosy	0.00179	0.00286	CcSEcCtD
Everolimus—Infestation—Thalidomide—leprosy	0.00178	0.00285	CcSEcCtD
Everolimus—Infestation NOS—Thalidomide—leprosy	0.00178	0.00285	CcSEcCtD
Everolimus—Acute coronary syndrome—Thalidomide—leprosy	0.00175	0.00281	CcSEcCtD
Everolimus—Abdominal pain—Dapsone—leprosy	0.00175	0.0028	CcSEcCtD
Everolimus—Body temperature increased—Dapsone—leprosy	0.00175	0.0028	CcSEcCtD
Everolimus—Renal failure—Thalidomide—leprosy	0.00175	0.0028	CcSEcCtD
Everolimus—Myocardial infarction—Thalidomide—leprosy	0.00174	0.00279	CcSEcCtD
Everolimus—Stomatitis—Thalidomide—leprosy	0.00173	0.00278	CcSEcCtD
Everolimus—Conjunctivitis—Thalidomide—leprosy	0.00173	0.00277	CcSEcCtD
Everolimus—Haematuria—Thalidomide—leprosy	0.0017	0.00271	CcSEcCtD
Everolimus—Epistaxis—Thalidomide—leprosy	0.00168	0.00269	CcSEcCtD
Everolimus—Sinusitis—Thalidomide—leprosy	0.00167	0.00267	CcSEcCtD
Everolimus—FKBP1A—TGF-beta Receptor Signaling—IFNG—leprosy	0.00164	0.0286	CbGpPWpGaD
Everolimus—Rhinitis—Thalidomide—leprosy	0.0016	0.00256	CcSEcCtD
Everolimus—Hepatitis—Thalidomide—leprosy	0.0016	0.00256	CcSEcCtD
Everolimus—Hypoaesthesia—Thalidomide—leprosy	0.00159	0.00254	CcSEcCtD
Everolimus—Pharyngitis—Thalidomide—leprosy	0.00159	0.00254	CcSEcCtD
Everolimus—Urinary tract disorder—Thalidomide—leprosy	0.00158	0.00252	CcSEcCtD
Everolimus—Oedema peripheral—Thalidomide—leprosy	0.00157	0.00252	CcSEcCtD
Everolimus—Urethral disorder—Thalidomide—leprosy	0.00157	0.00251	CcSEcCtD
Everolimus—Eye disorder—Thalidomide—leprosy	0.00149	0.00239	CcSEcCtD
Everolimus—Cardiac disorder—Thalidomide—leprosy	0.00148	0.00237	CcSEcCtD
Everolimus—Angiopathy—Thalidomide—leprosy	0.00145	0.00232	CcSEcCtD
Everolimus—Immune system disorder—Thalidomide—leprosy	0.00144	0.00231	CcSEcCtD
Everolimus—Mediastinal disorder—Thalidomide—leprosy	0.00144	0.0023	CcSEcCtD
Everolimus—Chills—Thalidomide—leprosy	0.00143	0.00229	CcSEcCtD
Everolimus—MTOR—IL12-mediated signaling events—CD8A—leprosy	0.00143	0.0249	CbGpPWpGaD
Everolimus—Alopecia—Thalidomide—leprosy	0.00141	0.00226	CcSEcCtD
Everolimus—Vomiting—Dapsone—leprosy	0.00141	0.00226	CcSEcCtD
Everolimus—MTOR—IL4-mediated signaling events—IL10—leprosy	0.00141	0.0245	CbGpPWpGaD
Everolimus—MTOR—IL4-mediated signaling events—CD40LG—leprosy	0.00141	0.0245	CbGpPWpGaD
Everolimus—Mental disorder—Thalidomide—leprosy	0.0014	0.00224	CcSEcCtD
Everolimus—Malnutrition—Thalidomide—leprosy	0.00139	0.00223	CcSEcCtD
Everolimus—Headache—Dapsone—leprosy	0.00139	0.00222	CcSEcCtD
Everolimus—Flatulence—Thalidomide—leprosy	0.00137	0.00219	CcSEcCtD
Everolimus—Dysgeusia—Thalidomide—leprosy	0.00136	0.00218	CcSEcCtD
Everolimus—Back pain—Thalidomide—leprosy	0.00135	0.00215	CcSEcCtD
Everolimus—Muscle spasms—Thalidomide—leprosy	0.00134	0.00214	CcSEcCtD
Everolimus—Nausea—Dapsone—leprosy	0.00132	0.00211	CcSEcCtD
Everolimus—Vision blurred—Thalidomide—leprosy	0.00131	0.0021	CcSEcCtD
Everolimus—Tremor—Thalidomide—leprosy	0.0013	0.00208	CcSEcCtD
Everolimus—Ill-defined disorder—Thalidomide—leprosy	0.00129	0.00206	CcSEcCtD
Everolimus—Anaemia—Thalidomide—leprosy	0.00129	0.00206	CcSEcCtD
Everolimus—Agitation—Thalidomide—leprosy	0.00128	0.00204	CcSEcCtD
Everolimus—Angioedema—Thalidomide—leprosy	0.00127	0.00203	CcSEcCtD
Everolimus—Malaise—Thalidomide—leprosy	0.00125	0.00201	CcSEcCtD
Everolimus—Syncope—Thalidomide—leprosy	0.00125	0.002	CcSEcCtD
Everolimus—Leukopenia—Thalidomide—leprosy	0.00124	0.00199	CcSEcCtD
Everolimus—Palpitations—Thalidomide—leprosy	0.00123	0.00197	CcSEcCtD
Everolimus—MTOR—Type II diabetes mellitus—TNF—leprosy	0.00123	0.0214	CbGpPWpGaD
Everolimus—Loss of consciousness—Thalidomide—leprosy	0.00122	0.00196	CcSEcCtD
Everolimus—Cough—Thalidomide—leprosy	0.00121	0.00194	CcSEcCtD
Everolimus—Convulsion—Thalidomide—leprosy	0.00121	0.00193	CcSEcCtD
Everolimus—Hypertension—Thalidomide—leprosy	0.0012	0.00192	CcSEcCtD
Everolimus—Arthralgia—Thalidomide—leprosy	0.00118	0.00189	CcSEcCtD
Everolimus—Myalgia—Thalidomide—leprosy	0.00118	0.00189	CcSEcCtD
Everolimus—Chest pain—Thalidomide—leprosy	0.00118	0.00189	CcSEcCtD
Everolimus—Anxiety—Thalidomide—leprosy	0.00118	0.00189	CcSEcCtD
Everolimus—Unspecified disorder of skin and subcutaneous tissue—Thalidomide—leprosy	0.00118	0.00188	CcSEcCtD
Everolimus—Discomfort—Thalidomide—leprosy	0.00117	0.00187	CcSEcCtD
Everolimus—MTOR—IL12-mediated signaling events—HLA-DRB1—leprosy	0.00116	0.0203	CbGpPWpGaD
Everolimus—Dry mouth—Thalidomide—leprosy	0.00116	0.00185	CcSEcCtD
Everolimus—Oedema—Thalidomide—leprosy	0.00114	0.00182	CcSEcCtD
Everolimus—Infection—Thalidomide—leprosy	0.00113	0.0018	CcSEcCtD
Everolimus—Shock—Thalidomide—leprosy	0.00112	0.00179	CcSEcCtD
Everolimus—Nervous system disorder—Thalidomide—leprosy	0.00111	0.00178	CcSEcCtD
Everolimus—Thrombocytopenia—Thalidomide—leprosy	0.00111	0.00178	CcSEcCtD
Everolimus—MTOR—IL2 signaling events mediated by PI3K—IL2—leprosy	0.00111	0.0194	CbGpPWpGaD
Everolimus—MTOR—IFN-gamma pathway—IFNG—leprosy	0.00111	0.0193	CbGpPWpGaD
Everolimus—Tachycardia—Thalidomide—leprosy	0.00111	0.00177	CcSEcCtD
Everolimus—Skin disorder—Thalidomide—leprosy	0.0011	0.00176	CcSEcCtD
Everolimus—Hyperhidrosis—Thalidomide—leprosy	0.0011	0.00176	CcSEcCtD
Everolimus—Anorexia—Thalidomide—leprosy	0.00108	0.00173	CcSEcCtD
Everolimus—FKBP1A—TGF-beta Receptor Signaling—TNF—leprosy	0.00106	0.0185	CbGpPWpGaD
Everolimus—Hypotension—Thalidomide—leprosy	0.00106	0.0017	CcSEcCtD
Everolimus—MTOR—Costimulation by the CD28 family—HLA-DRB1—leprosy	0.00105	0.0183	CbGpPWpGaD
Everolimus—Musculoskeletal discomfort—Thalidomide—leprosy	0.00103	0.00165	CcSEcCtD
Everolimus—Insomnia—Thalidomide—leprosy	0.00103	0.00164	CcSEcCtD
Everolimus—Paraesthesia—Thalidomide—leprosy	0.00102	0.00163	CcSEcCtD
Everolimus—Dyspnoea—Thalidomide—leprosy	0.00101	0.00162	CcSEcCtD
Everolimus—Somnolence—Thalidomide—leprosy	0.00101	0.00161	CcSEcCtD
Everolimus—Dyspepsia—Thalidomide—leprosy	0.000999	0.0016	CcSEcCtD
Everolimus—Decreased appetite—Thalidomide—leprosy	0.000987	0.00158	CcSEcCtD
Everolimus—Gastrointestinal disorder—Thalidomide—leprosy	0.00098	0.00157	CcSEcCtD
Everolimus—Fatigue—Thalidomide—leprosy	0.000979	0.00157	CcSEcCtD
Everolimus—Constipation—Thalidomide—leprosy	0.000971	0.00155	CcSEcCtD
Everolimus—Pain—Thalidomide—leprosy	0.000971	0.00155	CcSEcCtD
Everolimus—Feeling abnormal—Thalidomide—leprosy	0.000935	0.0015	CcSEcCtD
Everolimus—Gastrointestinal pain—Thalidomide—leprosy	0.000928	0.00148	CcSEcCtD
Everolimus—Body temperature increased—Thalidomide—leprosy	0.000897	0.00144	CcSEcCtD
Everolimus—Abdominal pain—Thalidomide—leprosy	0.000897	0.00144	CcSEcCtD
Everolimus—MTOR—CXCR4-mediated signaling events—HLA-DRB1—leprosy	0.000888	0.0155	CbGpPWpGaD
Everolimus—FKBP1A—Spinal Cord Injury—IFNG—leprosy	0.000879	0.0153	CbGpPWpGaD
Everolimus—MTOR—IL12-mediated signaling events—IFNG—leprosy	0.000849	0.0148	CbGpPWpGaD
Everolimus—Hypersensitivity—Thalidomide—leprosy	0.000836	0.00134	CcSEcCtD
Everolimus—MTOR—IL12-mediated signaling events—CD4—leprosy	0.00082	0.0143	CbGpPWpGaD
Everolimus—Asthenia—Thalidomide—leprosy	0.000814	0.0013	CcSEcCtD
Everolimus—Pruritus—Thalidomide—leprosy	0.000803	0.00128	CcSEcCtD
Everolimus—FKBP1A—Spinal Cord Injury—IL2—leprosy	0.000781	0.0136	CbGpPWpGaD
Everolimus—Diarrhoea—Thalidomide—leprosy	0.000777	0.00124	CcSEcCtD
Everolimus—MTOR—Regulation of Telomerase—IFNG—leprosy	0.000768	0.0134	CbGpPWpGaD
Everolimus—MTOR—IL12-mediated signaling events—IL2—leprosy	0.000754	0.0132	CbGpPWpGaD
Everolimus—Dizziness—Thalidomide—leprosy	0.000751	0.0012	CcSEcCtD
Everolimus—MTOR—Costimulation by the CD28 family—CD4—leprosy	0.000742	0.0129	CbGpPWpGaD
Everolimus—Vomiting—Thalidomide—leprosy	0.000722	0.00115	CcSEcCtD
Everolimus—Rash—Thalidomide—leprosy	0.000716	0.00114	CcSEcCtD
Everolimus—Dermatitis—Thalidomide—leprosy	0.000715	0.00114	CcSEcCtD
Everolimus—Headache—Thalidomide—leprosy	0.000711	0.00114	CcSEcCtD
Everolimus—MTOR—Regulation of Telomerase—IL2—leprosy	0.000682	0.0119	CbGpPWpGaD
Everolimus—Nausea—Thalidomide—leprosy	0.000674	0.00108	CcSEcCtD
Everolimus—MTOR—CXCR4-mediated signaling events—CD4—leprosy	0.000626	0.0109	CbGpPWpGaD
Everolimus—MTOR—Cardiac Hypertrophic Response—TNF—leprosy	0.000589	0.0103	CbGpPWpGaD
Everolimus—FKBP1A—Spinal Cord Injury—TNF—leprosy	0.000569	0.00992	CbGpPWpGaD
Everolimus—MTOR—Senescence and Autophagy in Cancer—IFNG—leprosy	0.000543	0.00946	CbGpPWpGaD
Everolimus—MTOR—Signaling by NGF—RIPK2—leprosy	0.00054	0.00942	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—CYLD—leprosy	0.000478	0.00834	CbGpPWpGaD
Everolimus—MTOR—MicroRNAs in cardiomyocyte hypertrophy—TNF—leprosy	0.00042	0.00732	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—PARK2—leprosy	0.000406	0.00708	CbGpPWpGaD
Everolimus—FKBP1A—Disease—SLC11A1—leprosy	0.000404	0.00705	CbGpPWpGaD
Everolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—TNF—leprosy	0.000387	0.00675	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—RIPK2—leprosy	0.000308	0.00537	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—TLR2—leprosy	0.000308	0.00537	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—RIPK2—leprosy	0.000296	0.00516	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—NOD2—leprosy	0.000279	0.00487	CbGpPWpGaD
Everolimus—MTOR—Immune System—CYLD—leprosy	0.000278	0.00486	CbGpPWpGaD
Everolimus—MTOR—Immune System—PARK2—leprosy	0.000246	0.00429	CbGpPWpGaD
Everolimus—MTOR—Disease—SLC11A1—leprosy	0.000227	0.00396	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—CD40LG—leprosy	0.000227	0.00395	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—CD8A—leprosy	0.000224	0.00391	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—RIPK2—leprosy	0.000206	0.0036	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—HLA-DRB1—leprosy	0.000183	0.00318	CbGpPWpGaD
Everolimus—MTOR—Immune System—TLR2—leprosy	0.000179	0.00313	CbGpPWpGaD
Everolimus—MTOR—Immune System—RIPK2—leprosy	0.000179	0.00313	CbGpPWpGaD
Everolimus—MTOR—Immune System—NOD2—leprosy	0.000163	0.00284	CbGpPWpGaD
Everolimus—MTOR—Immune System—CD40LG—leprosy	0.000137	0.0024	CbGpPWpGaD
Everolimus—MTOR—Immune System—CD8A—leprosy	0.000136	0.00237	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—CD4—leprosy	0.000134	0.00234	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—CD4—leprosy	0.000129	0.00225	CbGpPWpGaD
Everolimus—FKBP1A—Disease—CD4—leprosy	0.000128	0.00224	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—RIPK2—leprosy	0.000116	0.00202	CbGpPWpGaD
Everolimus—MTOR—Immune System—HLA-DRB1—leprosy	0.000111	0.00193	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—IL2—leprosy	8.26e-05	0.00144	CbGpPWpGaD
Everolimus—MTOR—Immune System—IFNG—leprosy	8.09e-05	0.00141	CbGpPWpGaD
Everolimus—MTOR—Immune System—CD4—leprosy	7.81e-05	0.00136	CbGpPWpGaD
Everolimus—MTOR—Disease—CD4—leprosy	7.21e-05	0.00126	CbGpPWpGaD
Everolimus—MTOR—Immune System—IL2—leprosy	7.18e-05	0.00125	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—SDHD—leprosy	6.71e-05	0.00117	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—IL2—leprosy	4.65e-05	0.00081	CbGpPWpGaD
